Perrigo EBITDA Margin 2010-2024 | PRGO
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Perrigo (PRGO) over the last 10 years. The current EBITDA margin for Perrigo as of December 31, 2024 is .
| Perrigo EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-12-31 |
$4.37B |
$0.45B |
10.24% |
| 2024-09-30 |
$4.39B |
$0.32B |
7.22% |
| 2024-06-30 |
$4.43B |
$0.31B |
6.95% |
| 2024-03-31 |
$4.56B |
$0.40B |
8.85% |
| 2023-12-31 |
$4.66B |
$0.51B |
11.04% |
| 2023-09-30 |
$4.65B |
$0.57B |
12.31% |
| 2023-06-30 |
$4.63B |
$0.54B |
11.71% |
| 2023-03-31 |
$4.56B |
$0.46B |
10.18% |
| 2022-12-31 |
$4.45B |
$0.42B |
9.37% |
| 2022-09-30 |
$4.40B |
$0.41B |
9.22% |
| 2022-06-30 |
$4.35B |
$0.79B |
18.25% |
| 2022-03-31 |
$4.20B |
$0.67B |
15.89% |
| 2021-12-31 |
$4.14B |
$0.72B |
17.35% |
| 2021-09-30 |
$4.09B |
$0.74B |
18.01% |
| 2021-06-30 |
$4.05B |
$0.40B |
9.91% |
| 2021-03-31 |
$4.02B |
$0.61B |
15.19% |
| 2020-12-31 |
$4.09B |
$0.65B |
15.85% |
| 2020-09-30 |
$3.39B |
$0.58B |
16.99% |
| 2020-06-30 |
$3.58B |
$0.56B |
15.57% |
| 2020-03-31 |
$3.78B |
$0.55B |
14.53% |
| 2019-12-31 |
$3.87B |
$0.57B |
14.65% |
| 2019-09-30 |
$4.71B |
$0.71B |
15.01% |
| 2019-06-30 |
$4.65B |
$0.53B |
11.46% |
| 2019-03-31 |
$4.69B |
$0.59B |
12.48% |
| 2018-12-31 |
$4.73B |
$0.65B |
13.78% |
| 2018-09-30 |
$4.82B |
$0.71B |
14.80% |
| 2018-06-30 |
$4.92B |
$1.00B |
20.32% |
| 2018-03-31 |
$4.97B |
$1.05B |
21.19% |
| 2017-12-31 |
$4.95B |
$1.02B |
20.64% |
| 2017-09-30 |
$4.99B |
$0.39B |
7.79% |
| 2017-06-30 |
$5.03B |
$-1.24B |
-24.70% |
| 2017-03-31 |
$5.13B |
$-1.21B |
-23.54% |
| 2016-12-31 |
$5.28B |
$-1.57B |
-29.69% |
| 2016-09-30 |
$2.93B |
$-1.77B |
-60.30% |
| 2016-06-30 |
$2.94B |
$-0.13B |
-4.46% |
| 2015-12-31 |
$1.22B |
$-0.04B |
-3.62% |
| 2015-09-30 |
$3.31B |
$1.72B |
51.87% |
| 2014-12-31 |
$3.03B |
$1.68B |
55.38% |
| 2014-09-30 |
$2.94B |
$1.52B |
51.79% |
| 2013-12-31 |
$2.83B |
$1.51B |
53.43% |
| 2013-09-30 |
$2.74B |
$1.39B |
50.84% |
| 2012-12-31 |
$2.43B |
$1.33B |
54.50% |
| 2012-09-30 |
$2.39B |
$1.28B |
53.48% |
| 2011-12-31 |
$2.26B |
$1.17B |
51.97% |
| 2011-09-30 |
$2.14B |
$1.05B |
48.95% |
| 2010-12-31 |
$1.90B |
$1.00B |
52.56% |
| 2010-09-30 |
$1.76B |
$0.85B |
48.44% |
| 2009-12-31 |
$1.62B |
$0.81B |
50.06% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED PRODUCTS |
$3.497B |
$4.373B |
|
Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business.
|
